A federal appeals court ruling last month which invalidated a patent covering Pfizer Inc.’s blockbuster hypertension drug Norvasc has spawned an effort to invalidate the patent in the Philippines.
The office of the U.S. Trade Representative has added Thailand to its annual list of the most serious offenders of intellectual property laws, citing the country’s recent decisions to issue compulsory licenses for several patented pharmaceutical products.
An association representing pharmacy benefit managers has released a study warning that a bill recently introduced to Congress would loosen antitrust laws and hand the independent drugstore lobby a “license to collude,” thus driving up health care costs by billions of dollars.
Danish pharmaceutical company H. Lundbeck A/S suffered a blow Friday when a British court ruled against it in a patent dispute with three generic makers over a patent for its top-selling antidepressant drug, Cipralex.
A federal appeals court panel has affirmed a lower court ruling that the United Kingdom, and not the United States, is the proper venue for a product liability suit brought by HIV-infected hemophiliacs against a handful of major drug companies.
A hospital operator that has been targeted in an antitrust suit alleging it conspired to “destroy” an affiliated doctor’s radiology practice has asked that the case be transferred to federal court.
The manufacturer of the acne drug Accutane scored a victory Wednesday, when Judge James S. Moody, Jr. granted its hotly contested motion to exclude any evidence related to “causality assessments” that address Accutane’s potential to cause inflammatory bowel disease.
Despite the U.S. Supreme Court’s ruling in KSR v. Teleflex, the U.S. Patent and Trademark Office has advised its examiners to not toss out the teaching-suggestion-motivation test altogether.
Brazil’s president has signed a compulsory license that overrides Merck & Co. Inc.’s patent on HIV/AIDS drug Efavirenz so that the country can import a generic version of the drug from India.
In a continued effort by lawmakers, labor unions and advocates to stop the U.S. Food and Drug Administration from closing six of its 13 field laboratories, two senators have proposed an amendment that would halt the plan until a study looks at the possible impacts.
AstraZeneca has filed a motion with the court overseeing the multidistrict products liability litigation over Seroquel in Florida, asking for permission to begin case-specific discovery, and warning “procedural chaos” will ensue if the requested relief is denied.
A federal appeals court has rejected Vonage Holdings Corp.’s claim that a patent infringement victory for rival Verizon Communications Inc. should be vacated because of a recent landmark ruling from the U.S. Supreme Court.
BioSafe Medical Technologies Inc. may be able to duck out of bankruptcy soon after negotiating a joint motion to dismiss that will see the home medical-testing company shelling out $6 million to pay off its unsecured creditors.
When it comes to regulatory and compliance issues involving the Food and Drug Administration, not many people have more expertise than Fred Branding. This month, Branding took his skills from McGuire Woods LLP to Reed Smith LLP, where he is now a partner in its health care practice group.
A German court on Thursday dismissed two suits brought by Schering AG shareholders in objection to the company’s merger with Bayer AG.
Mylan Pharmaceuticals Inc. has moved closer to regulatory approval to make generic Femara, the drug maker said Thursday, raising the stakes in a patent infringement suit Germany’s Novartis AG filed to protect the popular breast cancer treatment.
In order to help its clients face an increasingly complicated clinical trials regulatory environment, Epstein Becker & Green PC has created a team of legal, clinical and financial experts devoted specifically to solving clinical trials issues.
Pharmaceutical giant Merck & Co. Inc. has sued India’s Ranbaxy Laboratories Ltd. for infringing its patent on the antibacterial drug Primaxin.
The U.S. Food and Drug Administration should be able to approve some generic or follow-on biologic products if given the ability to do so, an agency official said at a hearing Wednesday.
An attempt by the Food and Drug Administration to block a subpoena sought by a small biotechnologies firm in a case brought by the U.S. Securities and Exchange Commission has failed, after a district court refused to grant the agency’s request for an injunction.